TrialJournal of hematology & oncology2013

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.

Moshe Talpaz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.